cagrilintide semaglutide combination cagrisema phase 3 results 2024 2025 Novo Nordisk has officially filed for FDA approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist with an amylin analogue, setting the stage for the next major Amylin Commands Weight Loss Attention

Its essential you partner with a PBM that can evolve from a simple processor to a true partner focused on net cost and clinical quality

This supports a more complete approach to obesity care: - Medication management - Protecting metabolic rate - Addressing biological adaptation Future therapies like FGF21 could fit into this multi-pathway model

2011 Apr 1;589(Pt 7):1509-10

Guidelines from the American Academy of Pediatrics and the Endocrine Society recommend intensive behavioral weight loss programs as first-line treatment for teen obesity, with pharmacotherapy considered only after documented failure of structured lifestyle modification over 6+ months